Select visualized or cytologic features to determine clinical candidacy for intervention.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Management of asymptomatic incidental neoplastic pancreatic cysts
To differentiate between low-risk surveillance and high-risk referral for EUS-FNA or surgery
To guide surveillance intervals in patients with stable IPMNs
Patient Population
Asymptomatic adults with incidental pancreatic cysts presumed to be Intraductal Papillary Mucinous Neoplasms (IPMNs). Not for patients with new-onset diabetes, unexplained pancreatitis, or symptomatic cysts.
Contraindications / Limitations
Symptomatic cysts — bypass this score and evaluate for surgery directly if malignancy is suspected
Strong family history of pancreatic cancer — guidelines are more aggressive in high-risk genetic populations
Known MD-IPMN (Main Duct) — the AGA guidelines primarily address BD-IPMN (Branch Duct) and stable mixed types
Section 2
Formula & Logic
Risk Categories
01
High-Risk Features: Cyst size ≥ 3 cm, dilated main pancreatic duct (>10 mm), or presence of an associated solid component (mural nodule).
02
Worrisome Changes: Any increase in cyst size > 3 mm per year, or new-onset duct dilation.
03
Surveillance Stability: Stability over 5 years without high-risk features allows for discontinuation of surveillance (a unique and somewhat controversial AGA recommendation).
Threshold Analysis
The AGA 2015 guidelines were designed to reduce "over-treatment" and "over-diagnosis" of low-risk cysts. They recommend high-confidence EUS-FNA only if there are ≥ 2 high-risk features, or if there is a significant change in a single feature.
Section 3
Pearls/Pitfalls
AGA vs. Fukuoka (2017)
The AGA 2015 criteria are significantly more conservative than the Fukuoka consensus. AGA aims to reduce unnecessary surgeries for low-grade dysplasia, whereas Fukuoka prioritizes sensitivity to ensure no high-grade dysplasia or early adenocarcinoma is missed.
The 5-Year Discontinuation Rule
AGA 2015 suggests stopping surveillance if a cyst < 3 cm has remained stable for 5 years. Many experts remain cautious with this approach, as late-onset progression has been documented in 5-10% of cases beyond the 5-year mark.
Surgical Referral Strategy
Refer for surgery if EUS-FNA shows high-grade dysplasia or adenocarcinoma
Consider surgery if both a solid component AND a dilated main duct are present
Refer to a high-volume pancreatic surgery centre for all intermediate/high-risk cyst removals
Section 4
Next Steps
Management Pathways
01
No High-Risk Features: MRI surveillance in 1 year, then every 2 years.
02
One High-Risk Feature: Consider EUS-FNA vs. MRI 6 months.
03
Two High-Risk Features: Mandatory EUS-FNA and surgical consultation.
Pathology Correlation
Cyst fluid CEA > 192 ng/mL confirms a mucinous cyst but does NOT predict malignancy. Only cytology (HGD/Cancer) or high-risk imaging features trigger surgical intervention.
Section 5
Evidence Appraisal
Core Guideline
American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.
Vege SS et al. • Gastroenterology. 2015;148(4):819-22. The foundational 2015 AGA algorithm.
Developed by the AGA Institute Clinical Practice and Quality Management Committee. It represented a major shift towards "rationalizing" surveillance, acknowledging that the majority of incidental pancreatic cysts will never progress to lethal cancer during a patient's remaining life span.
